STOCK TITAN

Viridian Therapeutics, Inc. - $VRDN STOCK NEWS

Welcome to our dedicated page for Viridian Therapeutics news (Ticker: $VRDN), a resource for investors and traders seeking the latest updates and insights on Viridian Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Viridian Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Viridian Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.24%
Tags
conferences clinical trial
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.96%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.96%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.93%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.52%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
conferences
Viridian Therapeutics, Inc.

Nasdaq:VRDN

VRDN Rankings

VRDN Stock Data

930.53M
47.94M
1.02%
100.99%
15.09%
Medical Laboratories
Health Care and Social Assistance
Link
United States of America
WALTHAM

About VRDN

miragen therapeutics, inc., (nasdaq: mgen), is a biopharmaceutical company discovering and developing innovative microrna (mirna)-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. the company leverages in-house expertise in mirna biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. at miragen, we recognize the importance of creating strategic relationships within the biotech and pharmaceutical industries and with academic institutions globally. this collaborative approach is making important contributions in our efforts to create mirna-targeting therapies. miragen’s areas of focus include hematological malignancies, pathological fibrosis, neuro-degeneration, and cardiovascular disease. in 2011, the company formed a strategic partnership with servier, a privately-run, french research